The prognostic differences between breast-conserving surgery and mastectomy in patients with invasive ductal carcinoma who achieved complete response following neoadjuvant chemotherapy: a propensity score matched analysis based on the SEER database.
{"title":"The prognostic differences between breast-conserving surgery and mastectomy in patients with invasive ductal carcinoma who achieved complete response following neoadjuvant chemotherapy: a propensity score matched analysis based on the SEER database.","authors":"Cheng Xiao, Yuanxin Zhang, Junyan Li","doi":"10.1186/s12957-025-03932-w","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The study investigates the prognostic differences between breast-conserving surgery (BCS) and mastectomy in patients with invasive ductal carcinoma of the breast who achieve a complete response (CR) after neoadjuvant chemotherapy.</p><p><strong>Methods: </strong>This study analyzed data from 9,411 patients diagnosed with invasive ductal carcinoma of the breast who achieved complete response following neoadjuvant chemotherapy, using data from the SEER database between 2010 and 2019, comprising 4,219 patients in the BCS group and 5,192 in the mastectomy group. Propensity score matching (PSM) was employed to control for confounding variables, and univariate and multivariate analyses were performed to identify variables associated with overall survival (OS) and cancer-specific survival (CSS). Kaplan-Meier survival curves were used to evaluate the prognosis of patients in the two groups.</p><p><strong>Results: </strong>The multivariate Cox regression analysis demonstrated that histological subtype, T stage, N stage, surgical method, and radiotherapy were risk factors for CSS, while age, histological subtype, T stage, and N stage were associated with OS (p < 0.05). Following matching, the Kaplan-Meier survival analysis curve suggested that the BCS group had higher CSS than the mastectomy group (p < 0.05), although there was no statistically significant difference in OS between the two groups (p = 0.16). Subgroup analysis revealed that, among patients aged ≤ 50, of White ethnicity, with grade 3 tumors, and HR+/HER-2- subtype, the BCS group exhibited superior CSS compared to the mastectomy group (p < 0.05).</p><p><strong>Conclusion: </strong>Patients with invasive ductal carcinoma of the breast who achieve complete response following neoadjuvant chemotherapy experience better CSS benefits with BCS compared to undergoing mastectomy.</p>","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":"23 1","pages":"269"},"PeriodicalIF":2.5000,"publicationDate":"2025-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12239254/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"World Journal of Surgical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12957-025-03932-w","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: The study investigates the prognostic differences between breast-conserving surgery (BCS) and mastectomy in patients with invasive ductal carcinoma of the breast who achieve a complete response (CR) after neoadjuvant chemotherapy.
Methods: This study analyzed data from 9,411 patients diagnosed with invasive ductal carcinoma of the breast who achieved complete response following neoadjuvant chemotherapy, using data from the SEER database between 2010 and 2019, comprising 4,219 patients in the BCS group and 5,192 in the mastectomy group. Propensity score matching (PSM) was employed to control for confounding variables, and univariate and multivariate analyses were performed to identify variables associated with overall survival (OS) and cancer-specific survival (CSS). Kaplan-Meier survival curves were used to evaluate the prognosis of patients in the two groups.
Results: The multivariate Cox regression analysis demonstrated that histological subtype, T stage, N stage, surgical method, and radiotherapy were risk factors for CSS, while age, histological subtype, T stage, and N stage were associated with OS (p < 0.05). Following matching, the Kaplan-Meier survival analysis curve suggested that the BCS group had higher CSS than the mastectomy group (p < 0.05), although there was no statistically significant difference in OS between the two groups (p = 0.16). Subgroup analysis revealed that, among patients aged ≤ 50, of White ethnicity, with grade 3 tumors, and HR+/HER-2- subtype, the BCS group exhibited superior CSS compared to the mastectomy group (p < 0.05).
Conclusion: Patients with invasive ductal carcinoma of the breast who achieve complete response following neoadjuvant chemotherapy experience better CSS benefits with BCS compared to undergoing mastectomy.
期刊介绍：
World Journal of Surgical Oncology publishes articles related to surgical oncology and its allied subjects, such as epidemiology, cancer research, biomarkers, prevention, pathology, radiology, cancer treatment, clinical trials, multimodality treatment and molecular biology. Emphasis is placed on original research articles. The journal also publishes significant clinical case reports, as well as balanced and timely reviews on selected topics.
Oncology is a multidisciplinary super-speciality of which surgical oncology forms an integral component, especially with solid tumors. Surgical oncologists around the world are involved in research extending from detecting the mechanisms underlying the causation of cancer, to its treatment and prevention. The role of a surgical oncologist extends across the whole continuum of care. With continued developments in diagnosis and treatment, the role of a surgical oncologist is ever-changing. Hence, World Journal of Surgical Oncology aims to keep readers abreast with latest developments that will ultimately influence the work of surgical oncologists.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
